No Cover Image

Journal article 1539 views 2729 downloads

Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial

Christopher Sorli, Shin-ichi Harashima, George M Tsoukas, Jeffrey Unger, Julie Derving Karsbøl, Thomas Hansen, Steve Bain Orcid Logo

The Lancet Diabetes & Endocrinology, Volume: 5, Issue: 4, Pages: 251 - 260

Swansea University Author: Steve Bain Orcid Logo

  • Sorli2017.pdf

    PDF | Accepted Manuscript

    Released under the terms of a Creative Commons Attribution Non-Commercial No Derivatives License (CC-BY-NC-ND).

    Download (866.67KB)
Published in: The Lancet Diabetes & Endocrinology
ISSN: 2213-8587
Published: Elsevier BV 2017
Online Access: Check full text

Tags: Add Tag
No Tags, Be the first to tag this record!
College: Faculty of Medicine, Health and Life Sciences
Issue: 4
Start Page: 251
End Page: 260